Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Liquidia Corporation (LQDA)

6.91   0.17 (2.52%) 03-31 16:00
Open: 6.76 Pre. Close: 6.74
High: 7 Low: 6.76
Volume: 766,298 Market Cap: 447(M)

Technical analysis

as of: 2023-03-31 4:20:15 PM
Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected.
Target: Six months: 9.09     One year: 10.62
Support: Support1: 6.7    Support2: 6.03
Resistance: Resistance1: 7.78    Resistance2: 9.09
Pivot: 6.87
Moving Average: MA(5): 6.86     MA(20): 6.86
MA(100): 6.31     MA(250): 5.7
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 51.4     %D(3): 51.6
RSI: RSI(14): 49.5
52-week: High: 8.78  Low: 3.25
Average Vol(K): 3-Month: 504 (K)  10-Days: 410 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ LQDA ] has closed below upper band by 46.7%. Bollinger Bands are 5.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 7.01 - 7.04 7.04 - 7.07
Low: 6.68 - 6.72 6.72 - 6.75
Close: 6.85 - 6.91 6.91 - 6.96

Company Description

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

Headline News

Sat, 25 Mar 2023
Industry Analysts Just Made A Captivating Upgrade To Their Liquidia Corporation (NASDAQ:LQDA) Revenue Forecasts - Yahoo Eurosport UK

Mon, 20 Mar 2023
Liquidia Corporation (NASDAQ:LQDA) Q4 2022 Earnings Call Transcript - Yahoo Finance

Thu, 16 Mar 2023
North American Morning Briefing : Some Calm -2- -

Mon, 13 Mar 2023
Insiders of Liquidia Corporation (NASDAQ:LQDA) are probably glad they bought last year as their US$2.6m investment now stands at US$3.2m - Simply Wall St

Fri, 10 Mar 2023
SVB shutdown forces Raleigh-Durham startups, public companies to ... - The Business Journals

Thu, 09 Mar 2023
Liquidia Corporation to Report Full Year 2022 Financial Results on ... - Kentucky Today

Financial Analysis

Price to Book Value: Underperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 65 (M)
Shares Float 46 (M)
% Held by Insiders 12.1 (%)
% Held by Institutions 52.7 (%)
Shares Short 2,660 (K)
Shares Short P.Month 3,040 (K)

Stock Financials

EPS -1.76
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1.63
Profit Margin (%) 0
Operating Margin (%) -316.5
Return on Assets (ttm) -23.5
Return on Equity (ttm) -54.9
Qtrly Rev. Growth -0.5
Gross Profit (p.s.) 0.15
Sales Per Share 0.21
EBITDA (p.s.) -0.66
Qtrly Earnings Growth 0
Operating Cash Flow -32 (M)
Levered Free Cash Flow -14 (M)

Stock Valuations

PE Ratio -3.93
PEG Ratio -0.1
Price to Book value 4.21
Price to Sales 32.32
Price to Cash Flow -14.14

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.